Established in 2014 as a social enterprise, Repositive is a technology company which has at its core a mission to increase discovery, access and sharing of genomic research data for the benefit of patients.
Repositive has created a public community and marketplace platform which catalogues over 1 million genomic research data sets and has a user base of academic and industry researchers from 90+ countries.
In 2017, the team initiated a collaboration with leading biopharma and CROs to launch the Repositive Cancer Models Platform to act as a broker of proprietary data and a network for oncology researchers. The Repositive Cancer Models Platform is the only one of its kind, being both globally accessible (not restricted to academics only or individual vendors) and searchable down to specific genomic characteristics. It caters for industry’s needs, such as privacy, security and IP protection, and oncology researchers can identify particular cancer models that optimally represent specific cancer types and targeted patient sub-populations – supporting better and faster research and development of cancer therapies.
In the media
15th April 2019
Preclinical Modeling of Tumor Metastasis and Resistance: Current Challenges and New Approaches
In 2013, Fiona founded DNAdigest as a charity to promote best practices for efficient and ethical data sharing, and in 2014, she co-founded Repositive to develop an online community platform and
28th March 2019
Cellesce scales organoid production for drug discovery using proprietary bioprocessing tech
Cellesce earlier this month also announced a collaboration with Repositive, a searchable, web-based platform that connects cancer researchers to the models and services.
21st March 2019
News 4 at Eleven : 21st March, 06:07 AM GMT
THE SENATOR SAYS EVERY EFFORT IS BEING MADE TO SEE THAT THE EFFORTS FOR IF REPOSITIVE TORE STAYS DEAD. >> MILITARY DAY AT THE NEVADA LEGISLATURE GIVES THOSE WHO SERVED A